Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize Care

Release Date: August 29, 2017
Expiration Date: August 29. 2018
Media: Internet - based


Activity Overview

There has been a recent deluge of pre-clinical and clinical data pertaining to the potential applications of poly (ADP-ribose) polymerase (PARP) inhibitor therapy in the treatment of patients with breast cancer. It is crucial for clinicians who treat patients with breast cancer to have a solid understanding of the mechanistic rationale for the use of these medications, to optimize their potential application. It is also important for clinicians to be aware of methods that may help to optimize patient selection for potential PARP inhibitor therapy and personalize breast cancer treatment approaches. The Medical Crossfire® format of this activity will feature leading experts in management of patients with breast cancer who will address multiple topics pertaining to the use of PARP inhibitors in the treatment of patients with breast cancer through a combination of didactic presentation and panel discussion.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

CME/CE Activity Table of Contents

  • Understanding the Genetics – DNA Damage Response Defects and Role to Molecularly Define Tumor Subtypes
    Commentary featuring Susan M. Domchek, MD
  • Historical Data Supporting the Use of PARP Inhibition
    Commentary featuring Jennifer Litton, MD
  • Translating Recent Clinical Trial Evidence on the Use of PARP Inhibition Into Practice
    Commentary featuring Mark Robson, MD and Tiffany Traina, MD
  • How Might PARP Inhibition Strategies Be Expanded in the Future?
    Commentary featuring Kimberly Blackwell, MD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe the mechanistic rationale to target PARP in the treatment of cancers
  • Determine current and emerging methods by which testing for germline/somatic mutations can be used and translated to the care of patients with breast cancer
  • Detail evolving efficacy and safety data concerning the application of PARP inhibitors in the treatment of ovarian and breast cancers including how this information can inform personalized decision making and counseling for patients with these tumors and their families
  • Place available evidence on the use of PARP inhibitor strategies in the clinical context of evolving treatment paradigms in the field of breast cancer management

Faculty, Staff, and Planners' Disclosures


Kimberly L. Blackwell, MD
Professor of Medicine
Assistant Professor of Radiation Oncology
Duke University Medical Center
Durham, NC

Disclosure: Grant Research Support: To Institution: Pfizer, Novartis, Genentech, Celgene; Consultant: Advaxis, Bayer, Celgene, Coherus, Eisai, Eli Lilly, Genentech, GI Therapeutics, MacroGenics, Merck, Novartis, Pfizer, Pierian Biosciences, Puma Biotechnology, Sandoz, Syndax.

Susan Domchek, MD
Director, MacDonald Women’s Cancer Risk Evaluation Center
Executive Director, Basser Center for BRCA
Basser Professor in Oncology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosure: Grant Research Support: Research Support to the University of Pennsylvania: AstraZeneca, AbbVie, Clovis Oncology, PharmaMar. Consultant: AstraZeneca.

Jennifer K. Litton, MD
Associate Professor
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant Research Support: Novartis, GlaxoSmithKline, AstraZeneca, Medivation/Pfizer, Genentech; Consultant: Medivation/Pfizer.

Mark E. Robson, MD
Attending Physician, Clinical Genetics and Breast Medicine Services
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant Research Support: To Institution: AstraZeneca, AbbVie, Medivation, Myriad Genetics; Consultant: AstraZeneca, McKesson.

Tiffany A. Traina, MD
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, NY

Disclosure: Grant Research Support: Eisai, Pfizer, Novartis Myriad Genetics, Innocrin Pharma, AstraZeneca, Astellas Pharma; Consultant: Eisai, Medivation, Pfizer, AstraZeneca, Bayer, Immunomedics, Merck, Astellas Pharma, Puma Biotechnology, Advaxis, Celgene.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By